Description
SX-682 is a novel CXCR1/2 inhibitor (IC50s: CXCR1 = 42 nM, CXCR2 = 20 nM).1It displayed robust synergistic activity with immune checkpoint blockade against castration resistant prostate cancer.2 It significantly reduced tumor burden in a Ptenfl/fl/Lkb1fl/fl mouse model of lung squamous cell cancer when used in combination with anti-PD1 therapy.3 SX-682 significantly inhibited trafficking of neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) enhancing anti-PD1 immune checkpoint blockade, T cell-based immunotherapy, and NK-cell immunotherapy.4,5
Uses
SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity[1].
References
[1] C. BOSS C R. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934)[J]. Expert Opinion on Therapeutic Patents, 2016, 26 1: 409-415. DOI:
10.1517/13543776.2016.1124087[2] XIN LU. Effective combinatorial immunotherapy for castration-resistant prostate cancer[J]. Nature, 2017, 543 7647: 728-732. DOI:
10.1038/nature21676[3] JULIA KARGL. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC.[J]. JCI insight, 2019. DOI:
10.1172/jci.insight.130850[4] LILLIAN SUN. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.[J]. JCI insight, 2019, 4 7. DOI:
10.1172/jci.insight.126853[5] SARAH GREENE. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.[J]. Clinical Cancer Research, 2020: 1420-1431. DOI:
10.1158/1078-0432.ccr-19-2625